David S. Boss

5.8k citations

24 papers · 4.4k indexed · 2 hit papers · h-index 14

Impact in

Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment

Papers in

Oncology 18
- HER2/EGFR in Cancer Research 6
- PARP inhibition in cancer therapy 5
- Cancer Treatment and Pharmacology 4
- Cancer-related Molecular Pathways 4
Applied Microbiology and Biotechnology 1

Co-authors: Jan H.M. Schellens Johann S. de Bono Peter C.C. Fong Timothy A. Yap Andrew Tutt James Carmichael Marja Mergui‐Roelvink Alan Ashworth
Journals: Journal of Clinical Oncology (8 papers)Clinical Cancer Research (2 papers)The Oncologist (2 papers)Annals of Oncology (2 papers)British Journal of Cancer (1 paper)
Partner nations: Netherlands United Kingdom United States

In The Last Decade

David S. Boss

24 papers receiving 4.3k citations

Hit Papers

align trajectories log scale

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval 2010 · 745 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Journal of Clinical Oncology
2009 New England Journal of Medicine

Peers

Countries citing papers authored by David S. Boss

Since Specialization

Citations

This map shows the geographic impact of David S. Boss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Boss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Boss more than expected).

Fields of papers citing papers by David S. Boss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Boss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Boss. The network helps show where David S. Boss may publish in the future.

Co-authors

The 25 scholars most cited alongside David S. Boss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David S. Boss Line = papers co-authored together David S. Boss links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Influence of point-of-care C-reactive protein testing on antibiotic prescription habits in primary care in the Netherlands Family Practice ·Tim J. Schuijt, David S. Boss, En-Yu Cho, Ayşe Y. Demir	2017	6
2	Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer Investigational New Drugs ·Ruud van der Noll, Willem M. Smit, A.N.M. Wymenga, David S. Boss, Mayer B. Grob, Alwin D. R. Huitema, Hilde Rosing, Matthijs M. Tibben, Lizhi Fang, Bridget Svancarek, Jos H. Beijnen, Jan H.M. Schellens	2015	8
3	Corporate Governance Oxford University Press eBooks ·David S. Boss, Brian L. Connelly, Robert E. Hoskisson, László Tihanyi	2013	5
4	A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours British Journal of Cancer ·David S. Boss, Hilary Glen, Jos H. Beijnen, E.C. Wright, R.S. Morrison, Jianzhao Geng, William Copalu, Antonina Joanna Mazur, J. Wanders, James P. O’Brien, Jan H.M. Schellens, T.R. Jeffry Evans	2012	150
5	Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors Clinical Cancer Research ·Pasi A. Jänne, David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon, Feng Guo, Steven Wong, Jane Liang, Stephen P. Letrent, Robert Millham, Ian Taylor, S. Gail Eckhardt, Jan H.M. Schellens	2011	149
6	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Journal of Clinical Oncology ·Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye Hit paper breakdown →	2010	745
7	Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors Annals of Oncology ·David S. Boss, Petronella O. Witteveen, Carlos Sáez-Díez Rebanal, Martijn P. Lolkema, Emile E. Voest, Paul K. Stockman, Ö. Ataman, David M. Wilson, Shampa Das, Jan H.M. Schellens	2010	85
8	Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors Clinical Cancer Research ·David S. Boss, V. Svane Knudsen, Letícia Daudt Pereira, Dick Pluim, Hilde Rosing, W.W. ten Bokkel Huinink, Jos H. Beijnen, Jan H.M. Schellens	2009	1
9	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers New England Journal of Medicine ·Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono Hit paper breakdown →	2009	2698
10	Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma Analytical Biochemistry ·Carola W.N. Damen, Els R. de Groot, M.F. Zebus, David S. Boss, Jan H.M. Schellens, Hilde Rosing, Jos H. Beijnen, Lucien A. Aarden	2009	62
11	Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours Annals of Oncology ·David S. Boss, Gary K. Schwartz, Mark R. Middleton, Dereck D. Amakye, Helen Swaisland, Rachel Midgley, Malcolm Ranson, Sarah Danson, Hilary Calvert, Ruth Plummer, C. Morris, Richard D. Carvajal, Lucian R. Chirieac, Jan H.M. Schellens, Geoffrey I. Shapiro	2009	50
12	Clinical Experience with Aurora Kinase Inhibitors: A Review The Oncologist ·David S. Boss, Jos H. Beijnen, Jan H.M. Schellens	2009	82
13	Application of PET/CT in the Development of Novel Anticancer Drugs The Oncologist ·David S. Boss, R.A. Valdés Olmos, Michiel Sinaasappel, Jos H. Beijnen, Jan H.M. Schellens	2008	42
14	Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC Journal of Clinical Oncology ·Pasi A. Jänne, Jan H.M. Schellens, Jeffrey A. Engelman, S. Gail Eckhardt, Robert Millham, L. Denis, Carolyn D. Britten, Siu‐Fun Wong, David S. Boss, D. Ross Camidge	2008	53
15	First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer Journal of Clinical Oncology ·Jan H.M. Schellens, Carolyn D. Britten, D. Ross Camidge, David S. Boss, Samuel Yeung Shan Wong, Sami Diab, I. Wayan Suryasa, R. P. Maguire, Stephen P. Letrent, Sabine Eckhardt	2007	4
16	A phase I dose finding study of E7080 in patients (pts) with advanced malignancies Journal of Clinical Oncology ·Hilary Glen, David S. Boss, T. R. J. Evans, M. Roelvink, Jose Saro, Eduardo Viana Lima, William Copalu, 輝野淵, Jéssyka Laura Galdino Costa, Jan H.M. Schellens	2007	7
17	First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers Journal of Clinical Oncology ·Timothy A. Yap, David S. Boss, Peter C.C. Fong, M. Roelvink, Andrew Tutt, J Carmichael, M. J. O'CONNOR, S.B. Kaye, J.H.M. Schellens, Johann S. de Bono	2007	49
18	Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152 Journal of Clinical Oncology ·Jan H.M. Schellens, David S. Boss, Prem Anand.D, Anthe S. Zandvliet, Jos H. Beijnen, Nicholas Jkmk Coney, C. Morris, David M. Wilson, Emile E. Voest	2006	47
19	503 POSTER Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evalutation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advance tumours European Journal of Cancer Supplements ·Johann S. de Bono, Peter C.C. Fong, David S. Boss, James Spicer, M. Roelvink, Andrew Tutt, Peter G. Mortimer, Matthew John O’Connor, Reilly Palmer, Roslyn Bakst	2006	2
20	Coronaviruses as Vectors: Stability of Foreign Gene Expression Journal of Virology ·Cornelis A. M. de Haan, Bert Jan Haijema, David S. Boss, Frank Heuts, Peter J. M. Rottier	2005	35

About David S. Boss

David S. Boss is a scholar working on Oncology, Applied Microbiology and Biotechnology, Cell Biology, Reproductive Medicine and Cancer Research, having authored 24 papers that have together received 4.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), PARP inhibition in cancer therapy (5 papers), DNA Repair Mechanisms (4 papers), Microtubule and mitosis dynamics (4 papers), Cancer Treatment and Pharmacology (4 papers), Cancer-related Molecular Pathways (4 papers), BRCA gene mutations in cancer (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Oncology (3.1k citations), Reproductive Medicine (713 citations), Cancer Research (778 citations), Molecular Biology (2.5k citations) and Genetics (939 citations). David S. Boss has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Jan H.M. Schellens, Johann S. de Bono, Peter C.C. Fong, Timothy A. Yap, Andrew Tutt, James Carmichael, Marja Mergui‐Roelvink, Alan Ashworth, Stan B. Kaye and Helen Swaisland. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Oncologist, Annals of Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact